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S U M M A R Y
Objectives: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) clones are
spreading rapidly among the population in many regions worldwide. Little information is available on
CA-MRSA in Mexico. The aim of this study was to identify CA-MRSA strains in the nose and throat of
healthy people in a Mexican community.
Methods: A total of 131 MRSA strains from the nose and throat obtained from healthy people in Mexico
City were characterized. The genes mecA, lukS-PV/lukF-PV, and ACME-arcA were detected by PCR.
Staphylococcal cassette chromosome mec (SCCmec), pulsed-ﬁeld gel electrophoresis (PFGE), and spa
typing were performed.
Results: Bacteria that had a Panton–Valentine leukocidin (PVL)-positive gene and SCCmec type IV or V
were designated as CA-MRSA strains. We found that 21.4% of MRSA strains were CA-MRSA and that the
percentage of CA-MRSA strains was similar in the nose and the throat. A great diversity of proﬁles was
found in the strains identiﬁed by PFGE pattern and spa typing. Only one strain similar to the USA300
genotype was found; this strain carried the ACME-arcA gene.
Conclusions: CA-MRSA strains were detected in the nose and throat of healthy people. We identiﬁed a
high level of genetic diversity among CA-MRSA strains in healthy people of Mexico City, which were
different from the USA and pandemic clone proﬁles.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Staphylococcus aureus, particularly methicillin-resistant S. aureus
(MRSA), is one of the most important nosocomial pathogens;
however, in the early 1990s, infections in healthy individuals
emerged among communities in Australia.1 These clones were
called community-acquired/associated MRSA (CA-MRSA).
CA-MRSA may cause many types of infection, ranging from mild
skin infections to severe abscesses, sepsis, and necrotizing
pneumonia.2 The most severe manifestations of disease may be
fatal, such as pneumonia, which occurs in approximately 1–2% of
CA-MRSA infections.3
Molecular typing studies have shown that CA-MRSA differs
from hospital-associated MRSA (HA-MRSA):4,5 these strains belong
to distinct genetic lineages and usually carry the staphylococcal
cassette chromosome mec (SCCmec) type IV, V, or VII6 and speciﬁc* Corresponding author. Tel.: +52 55 54837000ext.3848.
E-mail address: jbustos@correo.xoc.uam.mx (J. Bustos-Martı´nez).
1201-9712  2013 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.08.010virulence factors, such as Panton–Valentine leukocidin (PVL).7
CA-MRSA has also been shown to have higher expression levels of
toxins, phenol soluble modulins (PSMs), and hemolysins.2 The
USA300 clone can harbor the arginine catabolic mobile element
(ACME), and the arc gene cluster within the ACME may function as
a virulence or strain survival factor.8,9 In general, CA-MRSA is more
virulent compared to HA-MRSA due to the presence of various
virulence factors.10
CA-MRSA clones have been spreading rapidly in communities.
The CA-MRSA epidemic has led to an overall increase in MRSA
infections in the USA.11,12 The clone predominating in the USA is
USA300,12,13 whereas CA-MRSA infections in other parts of the
world are generally caused by other clones.
Today, ﬁve major PVL-positive CA-MRSA clones are dissemi-
nating worldwide: the ST1 clone is observed in Asia, Europe, and
the USA, the ST8 clone in Europe and the USA, the ST30 clone in
Australia, Europe, and South America, the ST59 clone in Asia and
the USA, and the ST80 clone in Asia, Europe, and the Middle-East.10
CA-MRSA has started to replace HA-MRSA in healthcare
facilities, especially in the USA and Taiwan where the CA-MRSA
prevalence is high.14,15
Staphylococci are ubiquitous colonizers of human epithelia and
mucous membranes and are opportunistic pathogens. About aociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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nose; there is a clear correlation between nasal colonization and
infection, indicating that most infections originate from colonizing
strains.16,17
Nasal colonization is the most signiﬁcant predictor of invasive
disease; however, in some studies, nearly half of patients carrying
S. aureus are colonized extranasally.18 The throat in particular may
be selectively colonized and escape current routine screening
programs.19–21
In a previous work, we investigated the presence of S. aureus in
the throat and anterior nares of healthy volunteers in Mexico City.
We found that 59.8% of the volunteers carried S. aureus, and of
these 8.6% had MRSA strains.22
The aim of this study was to identify CA-MRSA strains in these
same healthy people.
2. Materials and methods
2.1. Study population
Volunteers were recruited from schools and factories in Mexico
City. None of the volunteers had recently been hospitalized.
Volunteers were screened for nasal and throat carriage. The age of
the subjects ranged from 1 to 96 years (mean age 21 years); 54%
were females and 46% were males.22
Samples were collected in accordance with relevant guidelines
for ethical research design, conﬁdentiality, and the protection of
human subjects. The protocol was reviewed and approved by the
ethics and biosafety committees of the Universidad Auto´noma
Metropolitana-Xochimilco. All participants provided their in-
formed consent. Great care was taken to ensure that all people
understood that they would participate as volunteers; no academic
or economic incentives were offered.
2.2. Bacterial isolates
A total of 131 MRSA strains from 1039 S. aureus strains obtained
from healthy people in Mexico City were characterized: 65 strains
were from the nose (N) and 66 strains were from the throat (F). Of
these, 50 strains were exclusively from nasal carriers, 51 strains
were exclusively from throat carriers, and 30 strains were from
nasal and throat carriers.22
2.3. Detection of the mecA gene, PVL genes, and the ACME-arcA gene
mecA PCR was performed as described by Oliveira and de
Lencastre.23 The lukS-PV/lukF-PV genes (which encode PVL) were
detected by PCR as described by Lina et al.24 The ACME-arcA gene
PCR was performed as described previously.25 S. aureus NRS643
was used as positive control for these PCR assays.
2.4. SCCmec typing
SCCmec types were determined using two previously described
sets of multiplex PCR reactions.23,26 MRSA strains used as positive
controls for SCCmec types were ATCC BAA44 (Iberian MRSA clone),
ATCC BAA41 (New York MRSA clone), ATCC BAA39 (Hungarian
MRSA clone), and ATCC BAA1680 (USA300). Several mecA
amplicons were sequenced and compared to sequences listed on
the website SCCmec (http://www.staphylococcus.net).
2.5. Pulsed-ﬁeld gel electrophoresis (PFGE)
PFGE following SmaI digestion was performed according to a
protocol described elsewhere.27 DNA fragment patterns were
normalized using S. aureus strain NCTC8325. Samples were run ona CHEF-DR II system (Bio-Rad). Gels were photographed and
digitized using Bio-Rad Gel Doc.
PFGE patterns were analyzed with Gene Tool software and Gene
Directory software (Syngene, UK). Percent similarities were
obtained from the unweighted pair group with mathematical
average (UPMGA) based on Dice coefﬁcients. Band position
tolerance was set at 1.25%. The PFGE patterns were compared
using the criteria of Tenover et al.28 for bacterial strain typing, and
a similarity coefﬁcient >75% was selected to deﬁne possibly
related isolates.
All MRSA isolate PFGE patterns were compared with the PFGE
patterns of the following reference strains: NRS642 (USA100),
NRS651 (USA200), NRS643 (USA300), NRS123 (USA400), NRS648
(USA600), NRS386 (USA700), NRS653 (USA800), NRS652
(USA1000), NRS7450 (USA1000, SCCmec V), ATCC BAA44 (Iberian
MRSA clone), ATCC BAA41 (New York MRSA clone), and ATCC
BAA39 (Hungarian MRSA clone).
2.6. spa typing
The polymorphic X region of the protein A gene (spa) was
ampliﬁed and sequenced as described previously.29 Corresponding
spa-types were assigned using the SPA Searcher website (http://
seqtools.com). Ridom spa-types were subsequently assigned using
the spa typing website developed by Ridom GmbH (http://
spaserver.ridom.de/).
2.7. Statistical analysis
The Chi-square test was applied. Data were analyzed using JMP
9.0 statistical package (SAS Institute Inc., Cary, NC, USA). A critical
value of p < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Characterization of MRSA strains
Of the 131 MRSA isolates analyzed by multiplex PCR, the
SCCmec types of 129 (98.5%) could be determined. Four different
SCCmec types and a subtype were detected, including II, III, IV,
IVa, and V. The majority of the typeable MRSA isolates harbored
SCCmec type IV (66, 50.4%), followed by SCCmec type II (31,
23.6%) and SCCmec type IVa (28, 21.4%). The remaining SCCmec
types were present at very low frequencies, including types V (3,
2.3%) and III (1, 0.8%); SCCmec type I was not detected at all
(Table 1).
The genes for PVL (lukS-PV/lukF-PV) were present in isolates
harboring SCCmec types II, IV, IVa, and V, and were most frequently
observed in isolates harboring SCCmec type IV (22, 67%), followed
by SCCmec type IVa (5, 15%) and SCCmec type II (5, 15%), and
SCCmec type V (1, 3%) (Table 1).
The isolates were classiﬁed as CA-MRSA when they presented
the SCCmec type IV, or IVa, or V, and the lukS-PV/lukF-PV
genes. Twenty-eight CA-MRSA strains were found. This corre-
sponds to 21.4% (28/131) of MRSA strains or 2.6% of all isolates
(28/1039).
Similar numbers of strains with different SCCmec types and that
were PVL-positive were found in isolates exclusively from nasal
carriers and isolates exclusively from throat carriers; no statistical
signiﬁcance was observed (p = 0.2382) (Table 1). Therefore, the
percentage of CA-MRSA strains is similar in both niches: 22.4% (11/
49) in exclusive nasal carriers and 17.6% (9/51) in exclusive throat
carriers (p = 0.8657). The percentage was slightly higher – 25.8%
(8/31) – in isolates from nasal and throat carriers (Table 1).
The ACME-arcA gene was detected in only four CA-MRSA strains
(106F, 1251F, 1668F, and 1668N).
Table 1
Determination of SCCmec type, PVL genes, and CA-MRSA strains in MRSA isolates of the nose and throat of healthy people
Type of carrier PVL SCCmec type CA-MRSAa Total
II III IV IVa V ND
Exclusively nasal Pos 3 0 7 3 1 0 11 (22%) 49
Neg 6 1 14 13 1 0
Exclusively throat Pos 2 0 7 2 0 0 9 (18%) 51
Neg 15 0 14 8 1 2
Nasal and throat Pos 0 0 8 0 0 0 8 (26.7%) 31
Neg 5 0 16 2 0 0
Total 31 (23.6%) 1 (0.8%) 66 (50.4%) 28 (21.4%) 3 (2.3%) 2 (1.5%) 28 (21.4%) 131
PVL, Panton–Valentine leukocidin; CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; ND, not determined.
a Strains with SCCmec type IV, IVa, or V, and PVL-positive were classiﬁed as CA-MRSA.
Figure 1. SmaI-PFGE dendrogram comparing CA-MRSA strains isolated from the nose (N) and the throat (F) of healthy people. The CA-MRSA strains were compared with USA
(NRS) and pandemic (BAA) clones. SCCmec and spa types are indicated.
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The CA-MRSA strains were PFGE and spa typed. There was
considerable diversity in the PFGE patterns of these isolates,
demonstrating ongoing evolution. Almost all the proﬁles were
different from each other and were different from the characteris-
tic patterns of the USA and pandemic clones (Figure 1). Using the
relatedness level of >75%, determined by the criteria described by
Tenover et al.,28 only a few PFGE clusters with two strains could be
distinguished (Figure 1). Only the 1668N and 1668F strains were
possibly related to the USA300 clone, and the 133F strain was
possibly related to the USA100 clone. Identical proﬁles were
obtained only in strains from the nose and throat of the same
carrier, like 1668N and 1668F strains.
Several spa-types were found; only a few were repeated two or
three times: t-189, t-021, t-346, t-723, and t-922. Strain 1306N
had a new spa-type, t11978, with the repeat sequences
r07r13r23r12r21r17r34. Only the 1668N and 1668F strains had
spa-type t-008, characteristic of the USA300 clone (Figure 1).
Furthermore, these strains had the ACME-arcA gene like the
USA300 clone. Therefore, a strain related to the USA300 clone is
circulating in the nose and throat of healthy people in Mexico City.
4. Discussion
The recent establishment of CA-MRSA as a leading cause of
infection in healthy individuals is a matter of great concern.
Molecular epidemiology studies have highlighted the continuing
global evolution and spread of different MRSA clones.30
CA-MRSA spreads quickly in the outpatient population, with
the distinct domination of some clones in different periods,
countries, and continents. The most frequently identiﬁed clone,
ST8-IV (USA300), has been identiﬁed in the USA, South Africa, and
Asia. In Europe, the ST80-IV clone has mainly been present.6
Few studies have documented the epidemiology of CA-MRSA
infections in the community among Latin-Americans.31–33 CA-
MRSA has been described to occur in Colombia,34 Uruguay,35
Brazil,36 Ecuador, Peru, and Venezuela; in these countries, the
USA300 MRSA clone was described as the predominant CA-MRSA
between 2006 and 2008.31
In Mexico, molecular epidemiology studies have been per-
formed only for MRSA strains from hospitals. Aires de Sousa et al.,37
detected a unique clone associated with pediatric infections in
Mexico. This Mexican clone predominated in Mexico City between
1997 and 2000, but had been entirely substituted with the
multidrug-resistant New York/Japan clone by 2002.38 Isolates
collected between 1999 and 2003 in Guadalajara, Mexico were also
similar to the New York/Japan clone.39 Recently, a strain similar to
USA300 was found in a hospital in Nuevo Leo´n, Mexico.40
However, studies of CA-MRSA in healthy people in the
community have not been performed in Mexico and other
countries, and most studies of CA-MRSA have been conducted in
patients with infections.3,6,31,33,34,40–42 This study provides the ﬁrst
description of CA-MRSA in healthy people in Mexico City.
We found a great diversity of PFGE proﬁles in the isolated
strains, which are different from the proﬁles of the USA or
pandemic clones; this has also been found in other studies.34,42,43
The presence of the ACME-arcA gene was detected only in the
two strains that had a spa-type and PFGE proﬁle similar to the
USA300 clone. However, the ACME-arcA gene was also found in
two strains possibly related to each other by PFGE (106F and
1251F; spa-types t-527 and t-5747, respectively), but different
from the USA300 clone. This indicates that in this population
there are strains showing the ACME-arcA gene that are different
to the USA300 clone, as also found by Ellington et al. in
England.9We found only one strain that colonized the nose and throat of
the same person, which is related to the USA300 strain by PFGE, spa
typing, and ACME-arcA gene. These data are different from those
found in the USA, because in the USA, 1.5% of S. aureus carriers are
colonized with MRSA and 15.6% of these strains are USA300 or
USA400; the percentage of individuals carrying MRSA in the USA
has doubled since the appearance of CA-MRSA.44 In another study
in the USA, the proportion of USA300 isolates, indicative of
CA-MRSA, from MRSA nasal colonization increased from 8.0% in
2001–2002 to 17.2% in 2003–2004 in the non-institutionalized
US population.45 This difference in the number of similar strains to
the USA300 clone in our ﬁndings and data from the USA is not
surprising, because it was not until recently that a strain similar to
the USA300 genotype was identiﬁed in a hospital in the city of
Monterrey, Mexico.40This indicates that the spread of similar strains
to the USA300 clone in the Mexican population is not yet high.
However, continuous monitoring of this pathogen must be
performed.
The presence of CA-MRSA strains was similar in the nose and
throat. Therefore, both niches are likely to be similarly colonized by
CA-MRSA strains and both should be monitored.
In this study we identiﬁed a high level of genetic diversity
among CA-MRSA isolates from healthy people in Mexico City.
These results suggest that a high number of different CA-MRSA
clonal types are at risk of entering hospital environments through
the community.
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